Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Study Finds a Link Between Fatty Acid Ratios and Breast Cancer

June 1, 1996
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 6
Volume 5
Issue 6

WASHINGTON--A study of European women suffering from breast cancer has raised the intriguing possibility that the ratio of omega-3 to omega-6 polyunsaturated fatty acids (PUFA) may provide a way to predict an increased risk of the malignancy.

WASHINGTON--A study of European women suffering from breast cancerhas raised the intriguing possibility that the ratio of omega-3to omega-6 polyunsaturated fatty acids (PUFA) may provide a wayto predict an increased risk of the malignancy.

"We have looked at the balance between the two," saidepidemiologist Neil Simonsen, PhD, of the University of NorthCarolina at Chapel Hill, School of Public Health. "When wedo that, the ratio of omega-3 to omega-6 appears to be important.The higher the ratio, the more protective."

Therefore, he said, the balance between the two forms of PUFAsmay prove more relevant to the etiology of breast cancer thanthe absolute intake of a single fatty acid class.

Dr. Simonsen described the findings at Experimental Biology 96,an annual meeting of biological and biomedical researchers.

The PUFA ratio picture emerged from an analysis Dr. Simonsen conductedwith colleagues at the University of North Carolina and in Europe,which failed to confirm laboratory suggestions that a diet highin omega-6 fatty acids enhances mammary tumor activity.

The omega-6 fatty acids constitute the most common PUFA groupand include fats from corn oil and other vegetable sources. Thesecond PUFA family, omega-3, is found in fish, primarily oceanfishes.

Dr. Simonsen and his colleagues used data from EURAMIC (EuropeanStudy of Antioxidants, Myocardial Infarction, and Breast Cancer),a case-control investigation involving men and women. As partof the EURAMIC trial, investigators needle-biopsied adipose tissuefrom participants' buttocks to determine the antioxidant and fattyacid content.

Women From Five Nations

The researchers analyzed data from 698 women from five nations--Germany,Switzerland, Spain, The Netherlands, and Northern Ireland. Thesample included 291 women with primary breast cancer and 407 controlsselected from the same hospital catchment areas as the patients.

All were postmenopausal, with no major change in their weight,diet, or antioxidant use in the previous year. Other risk factorsfor breast cancer were considered in the analysis, including age,postmenopausal estrogen therapy, oral-contraceptive use, currentalcohol consumption, smoking status, parity, and age at menarcheand menopause.

Overall, the data indicated a statistically significant associationbetween higher concentrations of omega-6 in adipose cells andbreast cancer, but this was due to a high correlation found inone country--Spain. "If you exclude the patients from theSpanish center, the association goes away," he said.

An explanation may lie in the Spanish diet, which is high in oliveoil. Several studies have reported a protective association witholive oil consumption in southern European populations. The researchersfound that the Spanish women who had high levels of omega-6 alsohad low levels of oleic acid, a monounsat-urated fat dominantin olive oil--and vice versa.

The results for the Spanish women could indicate a reduction insome protective mechanism that eating olive oil provides, ratherthan a linkage between omega-6 and breast cancer, he said.

"It's hard to say that at the Spanish center that the findingis due to omega-6 and not to olive oil," Dr. Simonsen said."You see the same pattern whether you look at increasinglevels of polyunsat-urates or decreasing levels of oleic acid."

Right now, he said, "it's hard to make a smoking-gun recommendationfor clinicians." The new data may be making a further casefor olive oil, he said, "but we don't know if it's oliveoil or something else in that Mediterranean diet."

The study's most intriguing finding, in his view, is the possibilitythat the key factor in determining risk lies in the ratio of omega-3to omega-6.

The researchers are now in the midst of a more in-depth analysisof the omega-3/omega-6 ratio and other differences between thetwo PUFAs. They see this as more likely to provide illuminatinganswers than focusing on one fatty acid at a time. They also hopeto gain greater insights into the role of oleic acid and breastcancer.

"The real take-home message is that focusing in on just oneindividual type of fatty acid may not be the way to go,"Dr. Simonsen said. "We've got to look at the relationshipsbetween the different types."

Articles in this issue

Psychosocial Oncology May Benefit From System Reform
Know Your Partners, Know Your Goals in Joint Ventures Between Hospitals and Universities
Managed Care Reform: Wait Until Next Year for House, Senate
Converting Quality of Life Data to 'Q' Scores Allows Comparisons
Shorter Paclitaxel Infusions Add to Neuropathy Risk
Breast Cancer Mortality Rates Down
Pain Scale Resembling Thermometer May Be Easier to Use Than VAS
Immediate Hormone Therapy Improves Prostate Cancer Survival
New Test for Prostate Cancer Risk
Topotecan: Significant Activity in Ovarian Cancer
Prostate Cancer Guideline Classifies Patients By Risk Status
New Monograph Describes Racial/Ethnic Cancer Patterns in the US
Moral Challenges Ahead as Managed Care Marches On
One Doctor Tells His Experience With Hospital Mergers
BRCA2 Gene Mutations Linked to Ovarian Cancer Cases
Recent Videos
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content
Advertisement

Notably, improvements in both the ESR1 mutated population and the intent-to-treat population, including ESR1 wild type, were announced, and data will be presented at an upcoming scientific meeting.

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

Neil M. Iyengar, MD
October 24th 2025
Article

Read about recent advancements in breast cancer treatment, including new therapies and survival data, showcased at the upcoming ESMO 2025 Congress.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Dato-DXd May Be Next SOC in First-Line TNBC

Dato-DXd May Be Next SOC in First-Line TNBC

Kristi Rosa
October 20th 2025
Article

Datopotamab deruxtecan significantly enhanced survival rates in first-line treatment for metastatic triple-negative breast cancer.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.

PFS Benefit Occurs With Trastuzumab Rezetecan in HER2+ Breast Cancer

Jason M. Broderick
October 19th 2025
Article

Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.


T-DXd showed a consistent duration of response advantage vs THP regardless of prior treatment and mutational status among HER2+ breast cancer subgroups.

Subgroup Analysis Yields Clinically Meaningful Responses With T-DXd in HER2+ Breast Cancer

Ariana Pelosci
October 19th 2025
Article

T-DXd showed a consistent duration of response advantage vs THP regardless of prior treatment and mutational status among HER2+ breast cancer subgroups.

Related Content
Advertisement

Notably, improvements in both the ESR1 mutated population and the intent-to-treat population, including ESR1 wild type, were announced, and data will be presented at an upcoming scientific meeting.

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

Neil M. Iyengar, MD
October 24th 2025
Article

Read about recent advancements in breast cancer treatment, including new therapies and survival data, showcased at the upcoming ESMO 2025 Congress.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Dato-DXd May Be Next SOC in First-Line TNBC

Dato-DXd May Be Next SOC in First-Line TNBC

Kristi Rosa
October 20th 2025
Article

Datopotamab deruxtecan significantly enhanced survival rates in first-line treatment for metastatic triple-negative breast cancer.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.

PFS Benefit Occurs With Trastuzumab Rezetecan in HER2+ Breast Cancer

Jason M. Broderick
October 19th 2025
Article

Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.


T-DXd showed a consistent duration of response advantage vs THP regardless of prior treatment and mutational status among HER2+ breast cancer subgroups.

Subgroup Analysis Yields Clinically Meaningful Responses With T-DXd in HER2+ Breast Cancer

Ariana Pelosci
October 19th 2025
Article

T-DXd showed a consistent duration of response advantage vs THP regardless of prior treatment and mutational status among HER2+ breast cancer subgroups.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.